AUSTIN, Texas, 23 mai 2023 (GLOBE NEWSWIRE) — XBiotech Inc. (NASDAQ : XBIT) annonce aujourd’hui que la division de rhumatologie de la FDA a autorisé la société à débuter une étude clinique de phase II afin de tester Natrunix™ comme traitement de l’arthrite rhumatoïde.
NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.
